Menu

Blog

Jun 27, 2023

Rapamycin is the gold standard for longevity interventions

Posted by in categories: biotech/medical, life extension

It sucks that the primary reason this has not gone forward is because it is off patent.


This video is reproduced from a presentation I gave to the Euro-Geroscience Task Force “Challenges in Developing Geroscience Drug Trials” held March 23, 2022 in Toulouse, France. It gives an introduction to the state of research on rapamycin as a potential longevity and healthspan drug and some of the challenges and opportunities for clinical development.

Leave a reply